Vertex Pharmaceuticals (VRTX)
(Real Time Quote from BATS)
$462.24 USD
+2.24 (0.49%)
Updated Sep 24, 2024 11:24 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Earnings News For VRTX
-
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
-
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
-
Vertex: Q2 Earnings Snapshot
-
Vertex Reports Second Quarter 2024 Financial Results
-
Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report?
-
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
-
Vertex: Q1 Earnings Snapshot
-
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
-
Vertex Reports First Quarter 2024 Financial Results
-
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
-
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
-
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
-
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
-
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
-
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
-
Vertex: Q4 Earnings Snapshot
-
Vertex: Q4 Earnings Snapshot
-
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
-
Why Is Vertex (VRTX) Down 6.4% Since Last Earnings Report?
-
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
-
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates
-
Vertex: Q3 Earnings Snapshot
-
Vertex Reports Third Quarter 2023 Financial Results
-
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?